Identifying plausible adverse drug reactions using knowledge extracted from the literature

Journal of Biomedical Informatics

Volumn 52, Issue , 2014, Pages 293-310

  Shang, Ning ^a   Xu, Hua ^a   Rindflesch, Thomas C ^b   Cohen, Trevor ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b National Library of Medicine   (United States)

Author keywords

Distributional semantics; Literature based discovery; Pharmacovigilance; Predication based semantic indexing; Reflective random indexing

Indexed keywords

DRUG INTERACTIONS; INDEXING (OF INFORMATION); NATURAL LANGUAGE PROCESSING SYSTEMS; SEMANTICS;

DISTRIBUTIONAL SEMANTICS; LITERATURE-BASED DISCOVERIES; PHARMACOVIGILANCE; RANDOM INDEXING; SEMANTIC INDEXING;

DATA MINING;

LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADVERSE DRUG REACTION; ARTICLE; DATA BASE; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HEART INFARCTION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; NATURAL LANGUAGE PROCESSING; ALGORITHM; DATA MINING; MEDICAL RESEARCH; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SEMANTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; BIOMEDICAL RESEARCH; DATA MINING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDLINE; NATURAL LANGUAGE PROCESSING; ROC CURVE; SEMANTICS;

EID: 84919846618     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2014.07.011     Document Type: Article

References (157)

1. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356(9237):1255-1259.
2. Lazarou J., Pomeranz B., Corey P. Incidence of adverse drug reactions in hospitalized patients. JAMA: J Amer Med Assoc 1998, 279(15):1200-1205.
3. Hamilton R.A., Briceland L.L., Andritz M.H. Frequency of hospitalization after exposure to known drug-drug interactions in a medicaid population. Pharmacother: J Human Pharmacol Drug Ther 1998, 18(5):1112-1120.
4. Baker G.R., Norton P.G., Flintoft V., Blais R., Brown A., Cox J., et al. The Canadian adverse events study: the incidence of adverse events among hospital patients in Canada. Can Med Assoc J 2004, 170(11):1678-1686.
5. Bourgeois F.T., Mandl K.D., Valim C., Shannon M.W. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 2009, 124(4):e744-e750.
6. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22(2):151-185.
7. Rawlins M.D. Spontaneous reporting of adverse drug reactions. I: The data. Brit J Clin Pharmacol 1988, 26(1):1-5.
8. Rawlins M.D. Spontaneous reporting of adverse drug reactions. II:, Uses. Brit J Clin Pharmacol 1988, 26(1):7-11.
9. Van Puijenbroek E.P., Diemont W.L., van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf 2003, 26(5):293-301.
10. Hasford J., Goettler M., Munter K.-H., Müller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002, 55(9):945-950.
11. Alvarez-Requejo A., Carvajal A., Begaud B., Moride Y., Vega T., Arias L.M. Under-reporting of adverse drug reactions estimate based on a spontaneous reporting scheme and a sentinel system. Europ J Clin Pharmacol 1998, 54(6):483-488.
12. Wang X., Hripcsak G., Markatou M., Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Amer Med Info Assoc 2009, 16(3):328-337.
13. Trifirò G., Pariente A., Coloma P.M., Kors J.A., Polimeni G., Miremont-Salamé G., et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?. Pharmacoepidemiol Drug Saf 2009, 18(12):1176-1184.
14. Haerian K., Varn D., Vaidya S., Ena L., Chase H.S., Friedman C. Detection of pharmacovigilance-related adverse events using electronic health records and automated methods. Clin Pharmacol Ther 2012, 92(2):228-234.
15. Harpaz R., Vilar S., DuMouchel W., Salmasian H., Haerian K., Shah N.H., et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Amer Med Info Assoc 2013, 20(3):413-419.
16. Friedman C. Discovering novel adverse drug events using natural language processing and mining of the electronic health record. Lecture notes in computer science 2009, vol. 5651:1-5. Springer, Berlin Heidelberg. C. Combi, Y. Shahar, A. Abu-Hanna (Eds.).
17. Oliveira J.L., Lopes P., Nunes T., Campos D., Boyer S., Ahlberg E., et al. The EU-ADR web platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf 2013, 22(5):459-467.
18. Deftereos S.N., Andronis C., Friedla E.J., Persidis A., Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdisciplinary Rev: Systems Biol Med 2011, 3(3):323-334.
19. Bauer-Mehren A., van Mullingen E.M., Avillach P., del Carmen Carrascosa M., Garcia-Serna R., Piñero J., et al. Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol 2012, 8(4):e1002457.
20. Shetty K.D., Dalal S.R. Using information mining of the medical literature to improve drug safety. J Amer Med Info Assoc 2011, 18(5):668-674.
21. Merck, Merck announces voluntary worldwide withdrawal of VIOXX; 2004. http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf.
22. EMA. European medicines agency recommends suspension of Avandia, Avandamet and Avaglim, Press release; 2010.
23. Ye J.-p. Challenges in drug discovery for thiazolidinedione substitute. Acta Pharmaceut Sinica B 2011, 1(3):137-142.
24. Blind E., Dunder K., De Graeff P., Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia 2010, 54(2):213-218.
25. Anderson N., Borlak J. Correlation versus Causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS ONE 2011, 6(10):e25221.
26. WHO. Pharmacovigilance; 2010. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/index.html.
27. Ahmad S.R. Adverse drug event monitoring at the food and drug administration. J Gener Intern Med 2003, 18(1):57-60.
28. Kessler D.A., Natanblut S., Kennedy D., Lazar E., Rheinstein P., Anello C., et al. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA: J Amer Med Assoc 1993, 269(21):2765-2768.
29. Wysowski D.K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005, 165(12):1363.
30. Edwards I.R. The WHO Database - I. Drug Info J 1992, 26(4):477-480.
31. Bate A. The use of Bayesian confidence propagation neural network in pharmacovigilance. Dissertation, Umea University; 2003.
32. Edwards I.R., Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994, 10(2):93-102.
33. Collins F.S. Reengineering translational science: the time is right. Sci Transl Med 2011, 3(90):90cm17.
34. Bate A., Lindquist M., Edwards I., Olsson S., Orre R., Lansner A., et al. A Bayesian neural network method for adverse drug reaction signal generation. Europ J Clin Pharmacol 1998, 54(4):315-321.
35. Lindquist M., Edwards I.R., Bate A., Fucik H., Nunes A.M., Ståhl M. From association to alert - a revised approach to international signal analysis. Pharmacoepidemiol Drug Saf 1999, 8(Suppl. 1):S15-25.
36. Noren G.N., Bate A., Orre R., Edwards I.R. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Statist Med 2006, 25(21):3740-3757.
37. Lindquist M., Ståhl M., Bate A., Edwards I.R., Meyboom R.H. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000, 23(6):533-542.
38. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Amer Statist 1999, 53(3):177-190.
39. DuMouchel W., Pregibon D. Empirical Bayes screening for multi-item associations. Proceedings of the seventh ACM SIGKDD international conference on knowledge discovery and data mining 2001, 67-76. ACM.
40. Shakir S.A., Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 2002, 25(6):467-471.
41. Hill A.B. The environment and disease: association or causation?. Proceed Roy Society Med 1965, 58(5):295.
42. Doll R. Austin Bradford Hill. 8 July 1897-18 April 1991. Biogr Mem Fellows Roy Society 1994, 40:128-140.
43. Ward A.C. The role of causal criteria in causal inferences: Bradford Hill's "aspects of association". Epidemiol Perspect Innov 2009, 6(1):2.
44. Kleinberg S., Hripcsak G. A review of causal inference for biomedical informatics. J Biomed Info 2011, 44(6):1102-1112.
45. Perrio M., Voss S., Shakir S.A. Application of the Bradford Hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 2007, 30(4):333-346.
46. Swanson D.R. Undiscovered public knowledge. Libr Quart 1986, 103-118.
47. Swanson D.R. Two medical literatures that are logically but not bibliographically connected. J Amer Society Info Sci 1987, 38(4):228-233.
48. Weeber M., Klein H., de Jong-van den Berg L., Vos R. Using concepts in literature-based discovery: simulating Swanson's Raynaud-fish oil and migraine-magnesium discoveries. J Amer Society Info Sci Tech 2001, 52(7):548-557.
49. Bruza P.D., Weeber M. Literature-based discovery 2008, Springer.
50. Swanson D.R. Fish oil, Raynaud's syndrome, and undiscovered public knowledge. Perspect Biol Med 1986, 30(1):7.
51. Swanson D.R. Migraine and magnesium: eleven neglected connections. Perspect Biol Med 1988, 31(4):526-557.
52. Smalheiser N.R., Swanson D.R. Linking estrogen to Alzheimer's disease: an informatics approach. Neurology 1996, 47(3):809-810.
53. Srinivasan P, Rindflesch TC. Exploring text mining from MEDLINE. In: Proceedings of the AMIA symposium; 2002. p. 722-6.
54. Hristovski D, Friedman C, Rindflesch TC, Peterlin B. Exploiting semantic relations for literature-based discovery. In: AMIA annual symposium proceeding, vol. 2006; 2006. p. 349-53.
55. Yetisgen-Yildiz M., Pratt W. Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Info 2006, 39(6):600-611.
56. Sehgal A.K., Qiu X.Y., Srinivasan P. Analyzing LBD methods using a general framework. Literature-based discovery 2008, 75-100. Springer.
57. Yetisgen-Yildiz M., Pratt W. A new evaluation methodology for literature-based discovery systems. J Biomed Info 2009, 42(4):633-643.
58. Rindflesch T.C., Fiszman M. The interaction of domain knowledge and linguistic structure in natural language processing: interpreting hypernymic propositions in biomedical text. J Biomed Info 2003, 36(6):462-477.
59. Chen L., Friedman C. Extracting phenotypic information from the literature via natural language processing. Stud Health Tech Info 2004, 107:758-762.
60. Hristovski D., Friedman C., Rindflesch T.C., Peterlin B. Literature-based knowledge discovery using natural language processing. Literature-based discovery, no. 15 in information science and knowledge management 2008, 133-152. Springer, Berlin Heidelberg. P. Bruza, M. Weeber (Eds.).
61. Ahlers CB, Hristovski D, Kilicoglu H, Rindflesch TC. Using the literature-based discovery paradigm to investigate drug mechanisms. In: AMIA, Annual Symposium Proceedings, vol. 2007; 2007. p. 6-10.
62. Hristovski D, Burgun-Parenthoine A, Avillach P, Rindflesch TC. Towards using literature-based discovery to explain drug adverse effects. In: Quality of life through quality of information, MIE2012; 2012a.
63. Hristovski D, Burgun-Parenthoine A, Avillach P, Rindflesch TC. Using literature-based discovery to explain drug adverse effects. In: AMIA, annual symposium proceedings, vol. 1779; 2012b.
64. Aronson AR. Effective mapping of biomedical text to the UMLS metathesaurus: the MetaMap program. In: Proceedings of the AMIA symposium; 2001. p. 17-21.
65. Aronson A.R., Lang F.-M. An overview of MetaMap: historical perspective and recent advances. J Amer Med Info Assoc 2010, 17(3):229-236.
66. Rindflesch T.C., Fiszman M., Libbus B. Semantic interpretation for the biomedical research literature. Medical informatics, no. 8 in integrated series in information systems 2005, 399-422. Springer, US. H. Chen, S.S. Fuller, C. Friedman, W. Hersh (Eds.).
67. Aronson AR, Rindflesch TC. Semantic knowledge representation project. A report to the Board of Scientific Counselors; 1998.
68. Rindflesch T.C., Aronson A.R. Semantic processing for enhanced access to biomedical knowledge. Real World Semantic Web Appl 2002, 157-172.
69. Kilicoglu H, Fiszman M, Rosemblat G, Marimpietri S, Rindflesch TC. Arguments of nominals in semantic interpretation of biomedical text. In: Proceedings of the 2010 workshop on biomedical natural language processing; 2010. p. 46-54.
70. Lindsay R.K., Gordon M.D. Literature-based discovery by lexical statistics. J Amer Society Info Sci 1999, 50(7):574-587.
71. Cohen T., Widdows D. Empirical distributional semantics: methods and biomedical applications. J Biomed Info 2009, 42(2):390-405.
72. Cole R.J., Bruza P.D. A bare bones approach to literature-based discovery: an analysis of the Raynaud's/fish-oil and migraine-magnesium discoveries in semantic space. Lecture notes in computer science 2005, vol. 3735:84-98. Springer, Berlin/Heidelberg. A. Hoffmann, H. Motoda, T. Scheffer (Eds.).
73. Gordon M.D., Dumais S. Using latent semantic indexing for literature based discovery. J Amer Society Info Sci 1998, 49(8):674-685.
74. Cohen T., Schvaneveldt R., Widdows D. Reflective random indexing and indirect inference: a scalable method for discovery of implicit connections. J Biomed Info 2010, 43(2):240-256.
75. Kanerva P, Kristofersson J, Holst A. Random indexing of text samples for latent semantic analysis. In: Proceedings of the 22nd annual conference of the cognitive science society, vol. 1036; 2000. p. 1036-7.
76. Kanerva P. What we mean when we say "What's, the dollar of mexico?: prototypes and mapping in concept space". In: Proc AAAI, fall symp on quantum informatics for cognitive, social, and semantic processes; 2010.
77. Cohen T., Widdows D., Schvaneveldt R.W., Davies P., Rindflesch T.C. Discovering discovery patterns with predication-based semantic indexing. J Biomed Info 2012, 45(6):1049-1065.
78. Landauer T.K., Dumais S.T. A solution to Plato's problem: the latent semantic analysis theory of acquisition, induction, and representation of knowledge. Psych Rev 1997, 104(2):211.
79. Kuhn M., Campillos M., Letunic I., Jensen L.J., Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Systems Biol 2010, 6:343.
80. U.S. National Library of Medicine, National Institutes of Health, UMLS Terminology Services (UTS) API 2.0; 2012. http://uts.nlm.nih.gov/metathesaurus.html.
81. Wei W.-Q., Cronin R.M., Xu H., Lasko T.A., Bastarache L., Denny J.C. Development and evaluation of an ensemble resource linking medications to their indications. J Amer Med Info Assoc 2013, 20(5):954-961.
82. Kanerva P. Hyperdimensional computing: an introduction to computing in distributed representation with high-dimensional random vectors. Cognitive Computat 2009, 1(2):139-159.
83. Widdows D., Cohen T. Real, complex, and binary semantic vectors. Proc sixth intl symp on quantum interactions 2012, 24-35. Springer, Paris, France.
84. Kanerva P. The spatter code for encoding concepts at many levels. ICANN'94 1994, 226-229. Springer.
85. Plate T.A. Holographic reduced representations. IEEE Trans Neural Networks 1995, 6(3):623-641.
86. Kanerva P. Binary spatter-coding of ordered K-tuples. Artificial neural networks - ICANN 96 1996, 869-873. Springer.
87. Gayler RW. Vector symbolic architectures answer Jackendoff's challenges for cognitive neuroscience. arXiv preprint cs/0412059.
88. Wahle M., Widdows D., Herskovic J.R., Bernstam E.V., Cohen T. Deterministic binary vectors for efficient automated indexing of MEDLINE/PubMed abstracts. AMIA annual symposium proceedings 2012, vol. 2012. American Medical Informatics Association, 940.
89. Dumais S.T. Improving the retrieval of information from external sources. Behav Res Methods Instruments Computer 1991, 23(2):229-236.
90. Cohen T, Widdows D, Schvaneveldt RW, Rindflesch TC. Discovery at a distance: farther journeys in predication space. In: Bioinformatics and biomedicine workshops (BIBMW), 2012 IEEE international conference on; 2012b. p. 218-25.
91. Birkhoff G., Von Neumann J. The logic of quantum mechanics. Ann Math 1936, 823-843.
92. Widdows D., Peters S. Word vectors and quantum logic: experiments with negation and disjunction. Math Lang 2003, 8(141).
93. Cohen T., Widdows D., De Vine L., Schvaneveldt R., Rindflesch T.C. Many paths lead to discovery: analogical retrieval of cancer therapies. Quantum interaction 2012, 90-101. Springer.
94. Golub G.H., Van Loan C.F. Matrix computations 2012, vol. 3. JHU Press.
95. National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 Usa, Metathesaurus - Rich Release Format (RRF); 2009. http://www.ncbi.nlm.nih.gov/books/NBK9685/.
96. U.S. National Library of Medicine, National Institutes of Health, RxNorm API; 2013. http://rxnav.nlm.nih.gov/RxNormAPI.html.
97. Salton G., Fox E.A., Wu H. Extended Boolean information retrieval. Communications ACM 1983, 26(11):1022-1036.
98. Manning C.D., Raghavan P., Schütze H. Introduction to information retrieval 2008, vol. 1. Cambridge University Press, Cambridge.
99. Davis J, Goadrich M. The relationship between precision-recall and ROC curves. In: Proceedings of the 23rd international conference on Machine learning; 2006. p. 233-40.
100. Akbani R., Kwek S., Japkowicz N. Applying support vector machines to imbalanced datasets. Machine learning: ECML 2004 2004, 39-50. Springer.
101. Liu M., Wu Y., Chen Y., Sun J., Zhao Z., Chen X.-w., et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Amer Med Info Assoc 2012, 19(e1):e28-e35.
102. Hamblin M., Chang L., Fan Y., Zhang J., Chen Y.E. PPARs and the cardiovascular system. Antioxidants Redox Signaling 2009, 11(6):1415-1452.
103. Cheung B.M. Behind the rosiglitazone controversy. Exper Rev Clin Pharmacol 2010, 3(6):723-725.
104. Lygate C.A., Hulbert K., Monfared M., Cole M.A., Clarke K., Neubauer S. The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiov Res 2003, 58(3):632-637.
105. Shah N.D., Montori V.M., Krumholz H.M., Tu K., Alexander G.C., Jackevicius C.A., et al. Responding to an FDA, warning - geographic variation in the use of rosiglitazone. New England J Med 2010, 363(22):2081-2084.
106. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England J Med 2007, 356:2457-2471.
107. Berthet S., Olivier P., Montastruc J.-L., Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Pharmacol Toxicol 2011, 11(1):5.
108. U.S. Food and Drug Administration. Press announcements - FDA, requires removal of certain restrictions on the diabetes drug Avandia; 2013. .
109. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ: Brit Med J 2011, 342(7):d1309.
110. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28(7):1547-1554.
111. Khanderia U., Pop-Busui R., Eagle K.A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008, 42(10):1466-1474.
112. Bourg C.A., Phillips B.B. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother 2012, 46(2):282-289.
113. Bodenreider O., McCray A.T. Exploring semantic groups through visual approaches. J Biomed Info 2003, 36(6):414-432.
114. Brackenridge A.L., Jackson N., Jefferson W., Stolinski M., Shojaee-Moradie F., Hovorka R., et al. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabetic Med: J Brit Diabetic Assoc 2009, 26(5):532-539.
115. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Mouslech T.F., Hitoglou-Makedou A.D., Stafylas P.C., et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Meta: Clin Exp 2005, 54(9):1236-1242.
116. Vessby B., Kostner G., Lithell H., Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. Atherosclerosis 1982, 44(1):61-71.
117. van Wijk J., Coll B., Cabezas M.C., Koning E., Camps J., Mackness B., et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exper Pharmacol Physiol 2006, 33(12):1134-1137.
118. Gupta N., Singh S., Maturu V.N., Sharma Y.P., Gill K.D. Paraoxonase 1 (PON1), polymorphisms, haplotypes and activity in predicting CAD, risk in North-West Indian Punjabis. PLoS One 2011, 6(5):e17805.
119. Yoshida T., Kato K., Yokoi K., Oguri M., Watanabe S., Metoki N., et al. Association of genetic variants with myocardial infarction in Japanese individuals with different lipid profiles. Int J Mol Med 2010, 25(4):607-616.
120. Phillips G.B. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proceed Natl Acad Sci 1977, 74(4):1729-1733.
121. Kuller L., Arnold A., Tracy R., Otvos J., Burke G., Psaty B., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Throm Vas Biol 2002, 22(7):1175-1180.
122. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. New England J Med 2003, 349(21):1993-2003.
123. Lekhal S., Børvik T., Brodin E., Nordøy A., Hansen J.-B. Tissue factor-induced thrombin generation in the fasting and postprandial state among elderly survivors of myocardial infarction. Thromb Res 2010, 126(4):353-359.
124. De Caterina R., Talmud P.J., Merlini P.A., Foco L., Pastorino R., Altshuler D., et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis 2011, 214(2):397-403.
125. Chao L., Marcus-Samuels B., Mason M.M., Moitra J., Vinson C., Arioglu E., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000, 106(10):1221-1228.
126. Nadeau K.J., Ehlers L.B., Aguirre L.E., Reusch J.E.B., Draznin B. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Diabetes Obe Metab 2007, 9(5):714-723.
127. Suzuki S., Suzuki M., Sembon S., Fuchimoto D., Onishi A. Characterization of actions of octanoate on porcine preadipocytes and adipocytes differentiated in vitro. Biochem Biophys Res Communications 2013, 432(1):92-98.
128. Im MJ, Hoopes JE. Increases in dihydronicotinamide adenine dinucleotide (NADH) content and alpha-glycerophosphate dehydrogenase activity in epidermal wound healing. In: Proceedings of the society for experimental biology and medicine. Society for Experimental Biology and Medicine (New York, NY), vol. 173, issue no. 1; 1983. p. 17-20.
129. Johnson B.A., Wilson E.M., Li Y., Moller D.E., Smith R.G., Zhou G. Ligand-induced stabilization of PPARş monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 2000, 298(2):187-194.
130. Risérus U., Tan G.D., Fielding B.A., Neville M.J., Currie J., Savage D.B., et al. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-γ. Diabetes 2005, 54(5):1379-1384.
131. Otake K., Azukizawa S., Fukui M., Shibabayashi M., Kamemoto H., Miike T., et al. 4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity. Chem Pharmaceut Bull 2010, 59(10):1233-1242.
132. Egerod F.L., Svendsen J.E., Hinley J., Southgate J., Bartels A., Brünner N., et al. PPARα and PPARγ coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats. Toxicol Pathol 2009, 37(7):947-958.
133. Fliegner D., Westermann D., Riad A., Schubert C., Becher E., Fielitz J., et al. Up-regulation of PPARγ in myocardial infarction. Europ J Heart Fail 2008, 10(1):30-38.
134. Lee C.-H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144(6):2201-2207.
135. Gao D.-F., Niu X.-L., Hao G.-H., Peng N., Wei J., Ning N., et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-γ in vascular fibrosis. Biochem Pharmacol 2007, 73(2):185-197.
136. Tzameli I., Fang H., Ollero M., Shi H., Hamm J.K., Kievit P., et al. Regulated production of a peroxisome proliferator-activated receptor-γ ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem 2004, 279(34):36093-36102.
137. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., et al. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor. J Biol Chem 2005, 281(6):3398-3407.
138. Kim K.Y., Cheon H.G. Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor-activated Maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem 2006, 281(19):13503-13512.
139. Muhlhausler B.S., Duffield J.A., McMillen I.C. Increased maternal nutrition increases leptin expression in perirenal and subcutaneous adipose tissue in the postnatal lamb. Endocrinology 2007, 148(12):6157-6163.
140. Ding J., Nagai K., Woo J.-T. Insulin-dependent adipogenesis in stromal ST2 cells derived from murine bone marrow. Biosci Biotech Biochem 2003, 67(2):314-321.
141. Jung H.S., Youn B.-S., Cho Y.M., Yu K.-Y., Park H.J., Shin C.S., et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metab: Clin Exper 2005, 54(3):314-320.
142. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Communications 2003, 300(2):472-476.
143. Boyle P.J., King A.B., Olansky L., Marchetti A., Lau H., Magar R., et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002, 24(3):378-396.
144. Chen B., Wild D., Guha R. PubChem as a source of polypharmacology. J Chem Info Model 2009, 49(9):2044-2055.
145. Pauwels E., Stoven V., Yamanishi Y. Predicting drug side-effect profiles: a chemical fragment-based approach. BMC Bioinfo 2011, 12(1):169.
146. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucl Acids Res 2011, 39(Suppl. 1):D1035-D1041.
147. Kanehisa M., Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucl Acids Res 2000, 28(1):27-30.
148. Huang L.-C., Wu X., Chen J.Y. Predicting adverse side effects of drugs. BMC Genom 2011, 12(Suppl. 5):S11.
149. Tatonetti N.P., Patrick P.Y., Daneshjou R., Altman R.B. Data-driven prediction of drug effects and interactions. Sci Transl Med 2012, 4(125):125ra31.
150. Kuhn M., Al Banchaabouchi M., Campillos M., Jensen L.J., Gross C., Gavin A.-C., et al. Systematic identification of proteins that elicit drug side effects. Mol Syst Biol 2013, 9(1).
151. Kilicoglu H, Fiszman M, Rodriguez A, Shin D, Ripple A, Rindflesch TC. Semantic MEDLINE: a web application for managing the results of PubMed Searches. In: Proceedings of the third international symposium for semantic mining in biomedicine, vol. 2008; 2008. p. 69-76.
152. Ahlers CB, Fiszman M, Demner-Fushman D, Lang F-M, Rindflesch TC. Extracting semantic predications from Medline citations for pharmacogenomics. In: Pac symp biocomput, vol. 12; 2006. p. 209-20.
153. U.S. Food and Drug Administration, 2007 - FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia; 2007-11-14. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm.
154. Mahaffey K.W., Hafley G., Dickerson S., Burns S., Tourt-Uhlig S., White J., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Amer Heart J 2013, 166(2):240-249.
155. Lopes R.D., Dickerson S., Hafley G., Burns S., Tourt-Uhlig S., White J., et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD, trial: study design and conduct. Amer Heart J 2013, 166(2). 208-216.e28.
156. Thompson D. FDA to lift restrictions on diabetes drug Avandia; 2013. http://health.usnews.com/health-news/news/articles/2013/11/25/fda-to-lift-restrictions-on-diabetes-drug-avandia.
157. Herskovic JR, Bernstam EV. Using incomplete citation data for MEDLINE, results ranking. In: AMIA, annual symposium proceedings, vol. 2005; 2005. p. 316-20.